A Phase 1, Single Centre, Single-blind, Randomized, Placebo-controlled Parallel-group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Administration of Single Ascending Doses in Healthy Male Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Apr 2014
Price : $35 *
At a glance
- Drugs Tezepelumab (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors AstraZeneca
- 11 Feb 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Aug 2013 New trial record
- 01 Aug 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.